18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence

Fahad Marafi 1, Arun Sasikumar 2, Wael Fathallah 3, Abdulredh Esmail 1

Affiliations

01 January 2020

-

doi: 10.1097/RLU.0000000000002668

Abstract

A 64-year-old man with a known case of right parietal lobe glioblastoma multiforme operated on in August 2018 was referred for F-FDG PET/CT with a clinical suspicion of recurrence. He underwent F-FDG and F-PSMA 1007 scans. Both the scans showed intense tracer uptake in right parietal lobe lesion, which concurred with MRI findings of recurrent disease and was later proven on histopathologic examination as recurrence. Our case highlights the feasibility of F-PSMA 1007 PET/CT imaging of suspected glioblastoma recurrence. Considering its similarity to PSMA-617, it may be used as a surrogate imaging tracer for potential theranostic application using alpha or beta emitters.

Similar articles

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.PMID: 30843003

18F-PSMA 1007 Uptake in Brain Metastases From Breast Cancer.

Marafi F, Sasikumar A, Alfeeli M, Fathallah W.Clin Nucl Med. 2020 Feb;45(2):e77-e79. doi: 10.1097/RLU.0000000000002821.PMID: 31693624

Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis.

Sasikumar A, Joy A, Pillai MR, Nanabala R, Anees K M, Jayaprakash PG, Madhavan J, Nair S.Clin Nucl Med. 2017 Jan;42(1):e41-e48. doi: 10.1097/RLU.0000000000001451.PMID: 27846000

18F-PSMA 1007 in Suspected Renal Cell Carcinoma.

Marafi F, Sasikumar A, Al-Terki A, Alfeeli M.Clin Nucl Med. 2020 May;45(5):377-378. doi: 10.1097/RLU.0000000000003002.PMID: 32209880

Glioblastoma multiforme presenting as osteoblastic metastatic disease: case report and review of the literature.

Myers T, Egelhoff J, Myers M.AJNR Am J Neuroradiol. 1990 Jul-Aug;11(4):802-3.PMID: 2164320 Free PMC article. Review. No abstract available.

References

  1.  
    1. Sasikumar A, Joy A, Pillai MR, et al. Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors—preliminary analysis. Clin Nucl Med. 2017;42:e41–e48.
  2.  
    1. Sasikumar A, Kashyap R, Joy A, et al. Utility of 68Ga-PSMA-11 PET/CT in imaging of glioma—a pilot study. Clin Nucl Med. 2018;43:e304–e309.
  3.  
    1. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–495.
  4.  
    1. Freitag MT, Kesch C, Cardinale J, et al. Simultaneous whole-body (18)F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2018;45:340–347.
  5.  
    1. Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–688.
  6.  
    1. Giesel FL, Will L, Kesch C, et al. Biochemical recurrence of prostate cancer: initial results with [18F]PSMA-1007 PET/CT. J Nucl Med. 2018;59:632–635.
  7.  
    1. Kesch C, Vinsensia M, Radtke JP, et al. Intraindividual comparison of 18F-PSMA-1007 PET/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective, proof-of-concept study. J Nucl Med. 2017;58:1805–1810.
  8.  
    1. Seifert R, Schafigh D, Bögemann M, et al. Detection of local relapse of prostate cancer with 18F-PSMA-1007. Clin Nucl Med. 2019;44:e394–e395.
  9.  
    1. Pianou NK, Stavrou PZ, Vlontzou E, et al. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Hell J Nucl Med. 2019;22:6–9.
  10.  
    1. Giesel FL, Cardinale J, Schafer M, et al. (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43:1929–1930.

Page Navigation